Phase Forward Named to FORTUNE Small Business Fastest-Growing Public Companies
WALTHAM, MA
Up from 38th last year, Phase Forward, a provider of data management solutions for clinical trials and drug safety, has been included in the FORTUNE Small Business 100 list for the second consecutive year. The company ranked 20th among America’s fastest-growing small public companies and is also the top-ranked company in the state of Massachusetts and seventh among the 30 technology companies featured.
To compile the ninth annual list, FORTUNE Small Business asked financial research firm Zacks to screen annual reports for public companies with annual revenue of less than $200 million and a stock price of more than $1. Within that group, companies were ranked based on the past three years’ earnings growth, revenue growth, and stock performance. The list can be found in the July/August issue of FORTUNE Small Business.
“We’re pleased to be recognized by FORTUNE Small Business for the second year, which is a real testament to the caliber and commitment of our employees,” said Bob Weiler, Chairman and CEO, Phase Forward. “This past year has been an incredibly important year for us and we’ve worked hard to further expand our product lines to offer our customers a comprehensive, end-to-end approach to clinical trial data and safety management.”
Phase Forward closed 2008 with record revenues of $170.2 million, up 27 percent from 2007, and announced a 22 percent increase in GAAP revenues for the second quarter of 2009 over the same quarter last year.
About FORTUNE Small Business
FORTUNE Small Business is the premier magazine for-and about-small business owners, with the largest audience and rate base in the small business category. Through a partnership with American Express, FSB is distributed 10 times a year and reaches 1 million owners and partners of leading small businesses. With unmatched resources and access to the industry’s most innovative thinkers, FSB delivers best practices, connects small business owners to a community of their peers and arms them with the inspiration and actionable advice they need to succeed. FSB, along with FORTUNE, Money, and the Website CNNMoney.com, is part of The Fortune|Money Group. Time Inc. is a division of Time Warner, a leading media and entertainment company.
About Phase Forward
Phase Forward is a provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 290 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial
March 6th 2025Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a statistically significant and high level of pain reduction compared to placebo.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Data Show Efficacy of Tezspire Treating Chronic Rhinosinusitis with Nasal Polyps
March 4th 2025Phase III WAYPOINT trial shows Tezspire (tezepelumab) significantly reduces nasal polyp size and congestion severity in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, while also decreasing the need for surgery and systemic glucocorticoids.
